Pharma’s third-party logistics sector is undergoing a fundamental transformation, moving well beyond its traditional role of shifting pallets through wholesale distribution chains.
The industry is now contending with smaller patient populations, highly complex therapies, and direct-to-patient fulfillment models that demand an entirely different operational approach.
More than 4,000 gene, cell, and RNA therapies are currently in development, placing unprecedented logistical pressure on a distribution infrastructure that was never designed to handle them.
These therapies require a level of precision, chain-of-custody rigor, and individual patient coordination that conventional 3PL models simply cannot accommodate without significant reinvention.
Danny Williams, president of channel management and 3PL at EVERSANA, has a front-row view of how these pressures are reshaping the sector from the ground up.
Williams describes the core shift plainly: “I think one of the biggest shifts that we’ve seen from a model standpoint is this move away from traditional transactional logistics, moving full pallets of product that ultimately end up at a full-on wholesaler, and then moved down through a retail chain or specialty distributor.”
As therapies increasingly target rare and orphan disease populations, the logistics model must become far more integrated and patient-centric to remain fit for purpose.
Williams noted that it is now considered table stakes for manufacturers to manage a full order-to-cash life cycle, accounting for gross and net financial implications rather than simply moving product through a channel.
“I think almost everyone in the industry says it’s not a package, it’s a patient,” Williams said, adding that he is proud to be part of an industry where that sentiment holds true across providers.
AI has also crossed a meaningful threshold within pharma supply chains, shifting from experimental pilots into scaled operational deployment across forecasting and inventory management.
A recent survey of 100 heads of supply chain found adoption was highest in demand planning at 59%, inventory optimization at 57%, and logistics orchestration, though meaningful deployment requires governance and regulatory-grade guardrails.
Cell and gene therapies impose particularly stringent demands, including tight time and temperature windows, heightened chain-of-custody controls, and complex financial risk mitigation across manufacturers, 3PLs, and sites of care.
Direct-to-patient delivery is further expanding the 3PL operating model, requiring tighter integration with specialty pharmacy capabilities, telemedicine services, and patient-support workflows designed to sustain adherence.
EVERSANA has positioned itself to address this broader shift by pursuing what Williams describes as true end-to-end commercialization support rather than narrowly defined logistics execution.
Competitive advantage in this evolving landscape will increasingly fall to 3PLs that can unify infrastructure, data, technology, and execution into a scalable, regulated orchestration layer capable of delivering reliable, on-time patient outcomes.